Company
Headquarters: San Diego, CA, United States
Employees: 24
CEO: Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $30,000 |
| EBITDA | $-67,447,000 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | -225066.67% |
| Quarterly Revenue Growth | % |
ARS Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: SPRY wb_incandescent